These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32290045)

  • 21. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.
    D'Amico E; Patti F; Zanghì A; Chisari CG; Lo Fermo S; Zappia M
    Eur J Neurol; 2018 Dec; 25(12):1425-1431. PubMed ID: 29956427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pediatric Multiple Sclerosis in Rio de Janeiro: Secondary Progression and Disability.
    Cerqueira Pinto SC; Ferreira Vasconcelos CC; Aurenção JCK; Alvarenga MP; das Graças Gomes Camargo SM; Santos Thuler LC; Alvarenga RP
    Pediatr Neurol; 2019 May; 94():48-54. PubMed ID: 30850228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: a predictive model.
    Scott TF; Hackett CT; Quigley MR; Schramke CJ
    Clin Neurol Neurosurg; 2014 Dec; 127():86-92. PubMed ID: 25459249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009).
    Shirani A; Zhao Y; Kingwell E; Rieckmann P; Tremlett H
    Mult Scler; 2012 Apr; 18(4):442-50. PubMed ID: 21952097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical course of multiple sclerosis patients in Hong Kong.
    Lau KK; Wong WW; Sheng B; Yu IT; Fung BH; Li HL; Ma KF; Wong LK; Li PC
    J Neurol Sci; 2008 May; 268(1-2):78-82. PubMed ID: 18068191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting the course of relapsing-remitting MS using longitudinal disability curves.
    Achiron A
    J Neurol; 2004 Sep; 251 Suppl 5():v65-v68. PubMed ID: 15549358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses.
    Bin Sawad A; Seoane-Vazquez E; Rodriguez-Monguio R; Turkistani F
    Curr Med Res Opin; 2016 Dec; 32(12):1969-1974. PubMed ID: 27603119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Smoking Cessation and the Reduction of Disability Progression in Multiple Sclerosis: A Cohort Study.
    Tanasescu R; Constantinescu CS; Tench CR; Manouchehrinia A
    Nicotine Tob Res; 2018 Apr; 20(5):589-595. PubMed ID: 28402456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disability profile of MS did not change over 10 years in a population-based prevalence cohort.
    Pittock SJ; Mayr WT; McClelland RL; Jorgensen NW; Weigand SD; Noseworthy JH; Rodriguez M
    Neurology; 2004 Feb; 62(4):601-6. PubMed ID: 14981177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
    JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic indicators for long-term disability in multiple sclerosis patients.
    Damasceno A; Von Glehn F; Brandão CO; Damasceno BP; Cendes F
    J Neurol Sci; 2013 Jan; 324(1-2):29-33. PubMed ID: 23073568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Smoking does not influence disability accumulation in primary progressive multiple sclerosis.
    Javizian O; Metz LM; Deighton S; Koch MW
    Eur J Neurol; 2017 Apr; 24(4):624-630. PubMed ID: 28239937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis.
    Achiron A; Barak Y; Rotstein Z
    Mult Scler; 2003 Oct; 9(5):486-91. PubMed ID: 14582775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?
    Sidhom Y; Damak M; Riahi A; Hizem Y; Mrissa R; Mhiri C; Gouider R
    J Neurol Sci; 2014 Aug; 343(1-2):110-4. PubMed ID: 24980939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hospitalization is associated with subsequent disability in multiple sclerosis.
    Garland A; Metz LM; Bernstein CN; Peschken CA; Hitchon CA; Marrie RA
    Mult Scler Relat Disord; 2017 May; 14():23-28. PubMed ID: 28619426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression.
    Hohol MJ; Orav EJ; Weiner HL
    Mult Scler; 1999 Oct; 5(5):349-54. PubMed ID: 10516779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.